Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 18, 2023

BUY
$20.68 - $39.85 $24,816 - $47,820
1,200 Added 13.04%
10,400 $222,000
Q1 2023

Apr 19, 2023

SELL
$38.82 - $54.59 $3,882 - $5,459
-100 Reduced 1.08%
9,200 $372,000
Q3 2022

Oct 19, 2022

BUY
$48.29 - $71.27 $19,316 - $28,508
400 Added 4.49%
9,300 $482,000
Q1 2022

Apr 22, 2022

BUY
$56.06 - $74.11 $11,212 - $14,822
200 Added 2.3%
8,900 $675,000
Q3 2021

Oct 12, 2021

BUY
$41.02 - $58.65 $24,612 - $35,190
600 Added 7.41%
8,700 $494,000
Q2 2021

Jul 16, 2021

SELL
$43.76 - $53.11 $4,376 - $5,311
-100 Reduced 1.22%
8,100 $356,000
Q4 2020

Jan 11, 2021

SELL
$41.16 - $47.47 $4,116 - $4,747
-100 Reduced 1.2%
8,200 $345,000
Q3 2020

Oct 19, 2020

BUY
$43.36 - $53.53 $168,670 - $208,231
3,890 Added 88.21%
8,300 $380,000
Q1 2020

Apr 13, 2020

SELL
$40.22 - $62.0 $42,633 - $65,720
-1,060 Reduced 19.38%
4,410 $227,000
Q4 2019

Jan 17, 2020

SELL
$57.95 - $66.61 $24,918 - $28,642
-430 Reduced 7.29%
5,470 $338,000
Q1 2019

Apr 15, 2019

BUY
$69.08 - $105.66 $1,312 - $2,007
19 Added 0.32%
5,900 $564,000
Q4 2018

Jan 14, 2019

SELL
$65.41 - $84.65 $66,652 - $86,258
-1,019 Reduced 14.77%
5,881 $417,000
Q3 2018

Oct 16, 2018

BUY
$85.46 - $126.37 $34,184 - $50,548
400 Added 6.15%
6,900 $590,000
Q2 2018

Jul 18, 2018

BUY
$81.85 - $120.51 $8,184 - $12,051
100 Added 1.56%
6,500 $753,000
Q1 2018

Apr 18, 2018

BUY
$57.91 - $92.15 $17,373 - $27,645
300 Added 4.92%
6,400 $518,000
Q4 2017

Jan 16, 2018

BUY
$45.65 - $59.37 $13,695 - $17,811
300 Added 5.17%
6,100 $358,000
Q3 2017

Oct 16, 2017

BUY
$37.91 - $46.8 $219,877 - $271,440
5,800
5,800 $271,000

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $194M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Louisiana State Employees Retirement System Portfolio

Follow Louisiana State Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Louisiana State Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on Louisiana State Employees Retirement System with notifications on news.